Monocentric phase III clinical trial using citalopram (antidepressive compound fequently used in clinic) added to the standard of care (radio- combined with temozolomide chemotherapy and followed by temozolomide) for newly diagnosed glioblastoma patients (the most frequent malignant brain cancer) compared to the standard of care published in the literature

Monocentric phase III clinical trial using citalopram (antidepressive compound fequently used in clinic) added to the standard of care (radio- combined with temozolomide chemotherapy and followed by temozolomide) for newly diagnosed glioblastoma patients compared to the standard of care published in the literature - Phase III clinical trial using citalopram for glioblastoma patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2013-004705-59-BE

Enrollment

Registered

2013-11-21

Start date

2013-12-17

Completion date

Unknown

Last updated

2025-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Newly diagnosed glioblastoma (primary highly malignant brain cancer) patients Under treatment

Interventions

Trade Name: citalopram Product Name: citalopram Product Code: N06AB04 Pharmaceutical Form: Pillules

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Newly diagnosed glioblastoma Signed informed consent Age > = 18 years Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 35 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 15

Exclusion criteria

Exclusion criteria: Recurrent glioblastoma Citalopram related exclusion criteria Participation in another study

Design outcomes

Primary

Measure	Time frame
Main Objective: Phase III study comparing the standard of care radio- and temozolomide therapy for newly diagnosed glioblastoma patients (published in the literature) as compared to the same treatment adding citalopram each day 20 mg a day from the diagnosis to survival Survival analysis;Secondary Objective: Quality of live comparison knowing that the treatment of depression during cancer therapy could increase quality of live and even survival We will be helped by a psychiatrist practician;Primary end point(s): could citalopram added to the standard of care increase quality of live and survival of glioblastoma patients;Timepoint(s) of evaluation of this end point: survival	—

Measure

Time frame

Main Objective: Phase III study comparing the standard of care radio- and temozolomide therapy for newly diagnosed glioblastoma patients (published in the literature) as compared to the same treatment adding citalopram each day 20 mg a day from the diagnosis to survival Survival analysis;Secondary Objective: Quality of live comparison knowing that the treatment of depression during cancer therapy could increase quality of live and even survival We will be helped by a psychiatrist practician;Primary end point(s): could citalopram added to the standard of care increase quality of live and survival of glioblastoma patients;Timepoint(s) of evaluation of this end point: survival

—

Secondary

Measure	Time frame
Secondary end point(s): quality of live;Timepoint(s) of evaluation of this end point: quality of live questionnaire (EORTC) and with a psychiatric evaluation	—

Countries

Belgium

Contacts

Public ContactPr Florence Lefranc

Hôpital Erasme ULB

florence.lefranc@erasme.ulb.ac.be

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026